Patents Assigned to Amgen Inc.
  • Heterocyclic compounds as triggering receptor expressed on myeloid cells2 agonists and methods of use
    Patent number: 11718617
    Abstract: The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.
    Type: Grant
    Filed: November 30, 2022
    Date of Patent: August 8, 2023
    Assignees: AMGEN INC., Vigil Neuroscience, Inc.
    Inventors: Lara C. Czabaniuk, Timothy Hopper, Jonathan B. Houze, Gwenaella Rescourio, Vincent Santora, Haoxuan Wang, Ryan D. White, Alice R. Wong, Yongwei Wu
  • Fc-Containing Molecules Exhibiting Predictable, Consistent, and Reproducible Glycoform Profiles
    Publication number: 20230235024
    Abstract: The present invention relates to variant Fc-containing molecules, such as antibodies and Fc-fusion molecules, having glycosylation characteristics favorable to large-scale production of therapeutic molecules containing such variant Fc.
    Type: Application
    Filed: July 14, 2022
    Publication date: July 27, 2023
    Applicant: Amgen Inc.
    Inventors: Zhimei DU, Pranhitha REDDY, Randal B. BASS, Feng HE, William C. FANSLOW, III, Yuling ZHANG, Da REN, Randall R. KETCHEM
  • CYCLOPROPYL DIHYDROQUINOLINE SULFONAMIDE COMPOUNDS
    Publication number: 20230234948
    Abstract: The present invention provides a compound of Formula (I): (I); an enantiomer, diastereoisomer, atropisomer thereof, a mixture thereof, or a pharmaceutically acceptable salt thereof, that inhibits voltage-gated sodium channels, in particular NaV1.7. The compounds are useful for the treatment of diseases associated with the activity of sodium channels such as pain disorders, cough, and itch. Also provided are pharmaceutical compositions containing the compounds of the present invention. Also further provided is an atropi-selective preparation of said compounds of Formula (I), and intermediate thereof.
    Type: Application
    Filed: June 10, 2021
    Publication date: July 27, 2023
    Applicant: AMGEN INC.
    Inventors: BENJAMIN C. MILGRAM, ISSAC E. MARX, JOHN STELLWAGEN, WEI ZHAO, ALAN H. CHERNEY
  • HETEROALKYL DIHYDROQUINOLINE SULFONAMIDE COMPOUNDS
    Publication number: 20230227442
    Abstract: The present invention provides heteroalkyl dihydroquinoline sulfonamide compounds of Formula I, and pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the treatment of diseases associated with the activity of sodium channels such as pain disorders, cough, and itch. Also provided are pharmaceutical compositions containing compounds of the present invention.
    Type: Application
    Filed: June 11, 2021
    Publication date: July 20, 2023
    Applicant: AMGEN INC.
    Inventors: BENJAMIN C. MILGRAM, GWENAELLA RESCOURIO
  • MAMMALIAN CELL CULTURE
    Publication number: 20230227535
    Abstract: The invention provides a method for culturing mammalian cells. The method provides greater control over cell o growth to achieve high product titer cell cultures.
    Type: Application
    Filed: March 8, 2023
    Publication date: July 20, 2023
    Applicant: AMGEN INC.
    Inventors: Brian D. FOLLSTAD, Rebecca E. McCOY, Arvia E. MORRIS
  • Synthesis of omecamtiv mecarbil
    Patent number: 11702380
    Abstract: Provided herein are synthetic methods for the preparation of intermediates that are utilized in the synthesis of omecamtiv mecarbil dihydrochloride.
    Type: Grant
    Filed: March 9, 2022
    Date of Patent: July 18, 2023
    Assignee: Amgen Inc.
    Inventors: Sebastien Caille, James Murray, Kyle Quasdorf, Hannah Nguyen, Maria Victoria Silva Elipe, Ari Elizabeth Ericson
  • USE OF GDF15 FOR TREATING CARDIOMETABOLIC SYNDROME AND OTHER CONDITIONS
    Publication number: 20230210950
    Abstract: The present disclosure provides a method of treating cardiometabolic syndrome (CMS) with a GDF15 molecule. Also provided herein is a method of treating a cardiac or heart condition. In some embodiments, the GDF15 molecule is a GDF15-Fc fusion, in which a GDF15 region is fused to an Fc region, optionally via a linker.
    Type: Application
    Filed: October 2, 2020
    Publication date: July 6, 2023
    Applicant: AMGEN INC.
    Inventors: Murielle Marie V. ELLISON, Clarence H. HALE, Xin LUO, Marina STOLINA
  • Antibody constructs for CLDN18.2 and CD3
    Patent number: 11692031
    Abstract: The present invention relates to an antibody construct comprising a domain which binds to Claudin 18.2 (CLDN18.2) and another domain which binds to CD3. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for producing the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.
    Type: Grant
    Filed: August 2, 2019
    Date of Patent: July 4, 2023
    Assignees: AMGEN RESEARCH (MUNICH) GMBH, AMGEN INC.
    Inventors: Christoph Dahlhoff, Claudia Blümel, Johannes Brozy, Tobias Raum, Elisabeth Nahrwold, Tara Arvedson, Irwin Chen, Sandra Ross, Julie Bailis
  • ADMINISTRATION OF AN ANTI-ACTIVIN-A COMPOUND TO A SUBJECT
    Publication number: 20230201231
    Abstract: The present invention relates to methods of treating ovarian cancer in a subject by administering to the subject by evaluating the subject's expression levels of specific biomarkers or angiogenic an anti-activin-A compound, such as an anti-activin-A antibody or an activin-A-binding receptor. In some embodiments, at least two compounds are administered to the subject, where the first compound is an anti-activin A compound, and the second compound is a chemotherapeutic compound, for example capecitabine. The invention further relates to methods of identifying subjects for treatment factors.
    Type: Application
    Filed: December 22, 2022
    Publication date: June 29, 2023
    Applicants: AMGEN INC., Atara Biotherapeutics, Inc.
    Inventors: Huiquan HAN, Christopher Michael HAQQ, Isaac CIECHANOVER, Xiaolan ZHOU, John Zhao-Nian LU
  • Mammalian cell culture
    Patent number: 11685772
    Abstract: The invention provides a method for culturing mammalian cells. The method provides greater control over cell growth to achieve high product titer cell cultures.
    Type: Grant
    Filed: December 14, 2022
    Date of Patent: June 27, 2023
    Assignee: AMGEN INC.
    Inventors: Brian D. Follstad, Rebecca E. McCoy, Arvia E. Morris
  • Compounds that inhibit MCL-1 protein
    Patent number: 11685747
    Abstract: Provided herein are compounds that are useful intermediates that may used to synthesize myeloid cell leukemia 1 protein (Mcl-1) inhibitors. Also provided are Mcl-1 inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Grant
    Filed: October 21, 2020
    Date of Patent: June 27, 2023
    Assignee: AMGEN INC.
    Inventor: Nick A. Paras
  • Stabilized receptor polypeptides and uses thereof
    Patent number: 11685770
    Abstract: The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the stabilized polypeptides and proteins. Compositions and methods for treating muscle-wasting diseases and metabolic disorders are also provided.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: June 27, 2023
    Assignee: Amgen Inc.
    Inventors: Jeonghoon Sun, Lei-Ting Tony Tam, Mark Leo Michaels, Thomas Charles Boone, Rohini Deshpande, Yue-Sheng Li, Huiquan Han
  • METHODS FOR INCREASING MANNOSE CONTENT OF RECOMBINANT PROTEINS
    Publication number: 20230193340
    Abstract: The present invention relates to methods of modulating the mannose content of recombinant proteins.
    Type: Application
    Filed: February 22, 2023
    Publication date: June 22, 2023
    Applicant: AMGEN INC.
    Inventors: Jian WU, Sean DAVERN, Simina Crina PETROVAN, Michael Charles BRANDENSTEIN, Katherine Rose LINDAHL, Shawn Erik LILLIE
  • BTNL3 PROTEINS, NUCLEIC ACIDS AND ANTIBODIES AND USES THEREOF
    Publication number: 20230192802
    Abstract: The invention provides novel BTNL3 proteins, including multimers, fragments, fusion proteins, and variants. In addition, antibodies that can bind to BTNL3 proteins and nucleic acids encoding BTNL3 proteins are provided. Methods of making BTNL3 proteins using such nucleic acids are also provided. Uses for BTNL3 proteins, and agonists or antagonists thereof, are described.
    Type: Application
    Filed: August 23, 2022
    Publication date: June 22, 2023
    Applicant: Amgen Inc.
    Inventors: Heather ARNETT, Sabine Schadow ESCOBAR, Ryan Michael SWANSON, Joanne Louise VINEY
  • ACTIVATABLE POLYPEPTIDE COMPLEX
    Publication number: 20230183382
    Abstract: The present disclosure relates to activatable anti-EGFR, anti-CD3, heteromultimeric bispecific polypeptide complexes (HBPCs) and methods of making and using the same.
    Type: Application
    Filed: October 14, 2022
    Publication date: June 15, 2023
    Applicants: CytomX Therapeutics, Inc., Amgen, Inc.
    Inventors: Leila M. BOUSTANY, Madan M. PAIDHUNGAT, Ellaine Anne Mariano FOX, Sayantan MITRA, W. Michael KAVANAUGH, Raffaella BRIANTE, Jennitte LeAnn STEVENS
  • PROCESS OF MAKING IVABRADINE HYDROCHLORIDE DRUG PRODUCT
    Publication number: 20230181472
    Abstract: A new process for making ivabradine hydrochloride drug product reduces the amount of amorphous ivabradine hydrochloride in the drug product.
    Type: Application
    Filed: October 29, 2019
    Publication date: June 15, 2023
    Applicant: AMGEN INC.
    Inventors: Neil Obrad MACPHAIL, Angela Marie OLSOFSKY, Tiffany Lee THIEL, Yong XIE
  • Synthesis of Vinyl Cyclobutyl Intermediates
    Publication number: 20230183164
    Abstract: Provided herein are processes for synthesizing intermediates useful in preparing Mcl-1 inhibitors. In particular, provided herein are processes for synthesizing compound F, or a salt thereof, wherein R1 and OPG2 are described herein. Compound F can be useful in synthesizing compound A1, or a salt of solvate thereof, and compound A2, or a salt of solvate thereof.
    Type: Application
    Filed: May 4, 2021
    Publication date: June 15, 2023
    Applicant: AMGEN INC.
    Inventors: Austin G. SMITH, Michael T. CORBETT, Neil Fred LANGILLE, Kyle D. BAUCOM, Peter K. DORNAN, Gabrielle ST- PIERRE, Philipp C. ROOSEN, Sheng CUI, Roberto PROFETA
  • Gas permeable sealing member for drug container and methods of assembly
    Patent number: 11672733
    Abstract: Drug delivery devices, sealing members for containers housed within such drug delivery devices, and related methods of assembly are disclosed. The drug delivery device may include a housing, a container disposed in the housing and having an interior volume, a drug disposed in the interior volume, and a septum. The container may have an opening formed in an end surface and which communicates with the interior volume. The septum may include a proximal end inserted through the opening into the interior volume of the container. Additionally, the septum may include a distal end having a flange disposed outwardly of the proximal end and contacting the end surface of the container. At least an end portion of the flange may be made of a material that is permeable to a gaseous sterilizing agent.
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: June 13, 2023
    Assignee: AMGEN INC.
    Inventors: Cheng-Chieh Chou, Mingda Eu, Ren-Yo Forng, Wael Mismar
  • Handheld drug delivery device
    Patent number: D990668
    Type: Grant
    Filed: November 11, 2022
    Date of Patent: June 27, 2023
    Assignee: AMGEN INC.
    Inventors: Dylan Bourelle, Edgar Frausto, Clare O'Malley, Jakob Halkjaer Pedersen, Joshua J. Dudman
  • Handheld drug delivery device
    Patent number: D992109
    Type: Grant
    Filed: November 11, 2022
    Date of Patent: July 11, 2023
    Assignee: AMGEN INC.
    Inventors: Clare O'Malley, Edgar Frausto, Jakob Halkjaer Pedersen, Dylan Bourelle, Joshua J. Dudman